What is Pulmonx?
Pulmonx Corporation is at the forefront of developing and commercializing innovative treatments for severe emphysema, a debilitating form of COPD. Its flagship product, the Zephyr® Endobronchial Valve, is an FDA-approved implant designed to alleviate breathing difficulties by reducing lung hyperinflation. Complementing this are diagnostic and planning tools like the Chartis® Pulmonary Assessment System and StratX®/LungTraX® platforms, which leverage advanced imaging to identify suitable candidates for treatment. Having treated over 40,000 patients globally, Pulmonx has established itself as a leader in the interventional pulmonology sector, offering life-improving solutions for respiratory conditions.
How much funding has Pulmonx raised?
Pulmonx has raised a total of $421.1M across 10 funding rounds:
Series A
$7.1M
Series B
$20M
Series C
$32M
Series D
$10M
Private Equity
$10M
Debt
$20M
Private Equity
$50M
Multiple Rounds
$272M
Series A (2003): $7.1M with participation from MedVenture Associates and Montreux Equity Partners
Series B (2007): $20M led by DeNovo Ventures, MedVenture Associates, Latterell Venture Partners, and Montreux Equity Partners
Series C (2010): $32M supported by Kleiner Perkins Caufield & Byers, MedVenture Associates, De Novo Ventures, Latterell Venture Partners, Healthcap Venture Capital, and Montreux Equity Partners
Series D (2012): $10M, investors not publicly disclosed
Private Equity (2014): $10M, investors not publicly disclosed
Debt (2014): $20M with participation from Oxford Finance, LLC
Private Equity (2015): $50M, investors not publicly disclosed
Debt (2020): $17M supported by CIBC
Debt (2020): $65M featuring Partner Fund Management , L.P., Ally Bridge Group, ADAGE CAPITAL MANAGEMENT LP, Rock Springs Capital LLC, and HealthQuest Capital
Stock Issuance/Offering (2020): $190M, investors not publicly disclosed
Key Investors in Pulmonx
MedVenture Associates
MedVenture Associates, established in 1998, is a specialized entity in medical technology, focusing on the design, development, and manufacturing of minimally invasive catheter-based devices for various medical markets.
Montreux Equity Partners
Montreux Equity Partners specializes in high-growth, commercial-stage companies, aiming to accelerate their scale and drive growth through strategic investments in innovative products and technologies.
Kleiner Perkins Caufield & Byers
Kleiner Perkins is a prominent venture capital firm that invests in early and growth-stage technology and life science companies, providing capital and operational support from seed to IPO.
What's next for Pulmonx?
The recent major strategic investment in Pulmonx signals a strong validation of its technology and market position. This influx of capital is expected to fuel further expansion of its commercial reach, accelerate research and development for next-generation devices, and potentially support broader clinical adoption of its minimally invasive emphysema treatments. As the company continues to grow, it is poised to further solidify its leadership in the interventional pulmonology space, addressing a significant unmet need in respiratory care.
See full Pulmonx company page
